Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
대표청구항▼
What is claimed is: 1. A method for treating macular edema in a human, the method comprising administering transsclerally to an eye of the human an amount of rapamycin effective to treat macular edema, wherein the rapamycin is administered transsclerally by placement within or proximate to a sclera
What is claimed is: 1. A method for treating macular edema in a human, the method comprising administering transsclerally to an eye of the human an amount of rapamycin effective to treat macular edema, wherein the rapamycin is administered transsclerally by placement within or proximate to a sclera of the eye. 2. The method of claim 1, wherein the sclera has an outer scleral surface and the rapamycin is administered transsclerally by placement of a rapamycin containing delivery system proximate to the outer scleral surface. 3. The method of claim 2, wherein the rapamycin containing delivery system comprises a solid rapamycin core. 4. The method of claim 3, wherein the rapamycin containing delivery system further contains a backing portion that is substantially impermeable to rapamycin. 5. The method of claim 2, wherein the rapamycin containing delivery system comprises a suspension of particles of rapamycin. 6. The method of claim 5, wherein the particles of rapamycin have an average diameter of less than about 50 μm. 7. The method of claim 2, wherein the rapamycin containing delivery system comprises rapamycin dispersed in a polymer implant. 8. The method of claim 7, wherein the polymer implant is a biodegradable polymer implant. 9. The method of claim 7, wherein the polymer implant is a non-biodegradable polymer implant. 10. The method of claim 8 or claim 9, wherein the polymer implant further comprises a rapamycin impermeable backing. 11. The method of claim 8 or claim 9, wherein the polymer implant is shaped as a suture. 12. The method of claim 11, wherein the suture has a length of less than about 10 cm and a diameter of less than about 2 mm. 13. The method of claim 8 or claim 9, wherein the polymer implant is shaped as a coiled fiber. 14. The method of claim 13, wherein the coiled fiber has a length of less than about 5 cm and a diameter of less than about 1 mm. 15. The method of claim 8 or claim 9, wherein the polymer implant is shaped as a disk. 16. The method of claim 8 or claim 9, wherein the polymer implant has a scleral surface portion for placement on the outer scleral surface of the eye and the scleral surface portion has an area through which the rapamycin is delivered to the outer scleral surface of less than about 0.5 cm2. 17. The method of claim 8 or claim 9, wherein the polymer implant has a scleral surface portion for placement on the outer scleral surface of the eye, and the scleral surface portion comprises a bioadhesive layer. 18. The method of claim 8 or claim 9, wherein the polymer implant has a scleral surface portion comprises a number of protrusions, and whereby the scleral surface portion of the polymer implant anchors the polymer implant to the outer scleral surface of the eye. 19. The method of claim 8 or claim 9, wherein the polymer implant comprises a rapamycin containing portion coated with a coating, and wherein the concentration of rapamycin in the coating is less than the concentration of rapamycin in the rapamycin containing portion. 20. The method of claim 19, wherein the concentration of rapamycin in the coating is such that release of rapamycin from the coating does not deliver a wound healing inhibiting amount of rapamycin. 21. The method of claim 2, wherein the rapamycin containing delivery system comprises rapamycin dissolved in a solvent. 22. The method of claim 2, wherein the rapamycin containing delivery system delivers the rapamycin transsclerally in an amount sufficient to maintain an amount effective to treat macular edema for an extended period of time. 23. The method of claim 22, wherein the rapamycin containing delivery system delivers the rapamycin transsclerally in an amount sufficient to treat macular edema for at least about three weeks. 24. The method of claim 2, claim 5, or claim 21, wherein the rapamycin is administered transsclerally to the eye by subconjunctival or subtenon placement of the rapamycin containing delivery system. 25. The method of claim 24, wherein the rapamycin is administered transsclerally to the eye by subconjunctival injection of the rapamycin containing delivery system. 26. A method for treating macular edema in a human, comprising administering a composition to an eye of the human by subconjunctival or subtenon placement of the composition, wherein the composition comprises an amount of rapamycin effective to treat macular edema. 27. The method of claim 26, wherein the composition comprises a suspension of particles of rapamycin. 28. The method of claim 26, wherein the composition comprises rapamycin dissolved in a solvent. 29. The method of claim 21 or claim 28, wherein the solvent comprises polyethylene glycol. 30. The method of claim 29, wherein the solvent further comprises ethanol. 31. The method of claim 27 or claim 28, wherein the composition is administered to the eye by subconjunctival injection.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (123)
Zhang,Mingqiang; Sheridan,Rose Mary, 39-desmethoxyrapamycin, compositions and methods of use thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Osbakken,Robert S.; Hale,Mary Anne; Leivo,Frederick T.; Munk,James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Peyman Gholam A. (New Orleans LA) Yang Dachuan (New Orleans LA) Khoobehi Bahram (New Orleans LA), Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Armistead David A. (Maynard) Boger Joshua S. (Concord) Meyers Harold V. (Lexington) Saunders Jeffrey O. (Littleton) Tung Roger D. (Cambridge MA), Immunosuppressive compounds.
Gregory, Susan A; Isakson, Peter C; Anderson, Gary, Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin.
Steiner Joseph P. (Hampstead MD) Snyder Solomon (Baltimore MD) Hamilton Gregory S. (Catonsville MD), Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth.
Wright,Carol; Llanos,Gerard H.; Rakos,Ronald; King,Kristin; Falotico,Robert, Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent.
Luly Jay R. (Libertyville IL) Kawai Megumi (Libertyville IL) Or Yat S. (Libertyville IL) Wiedeman Paul (Libertyville IL) Wagner Rolf (Gurnee IL), Macrocyclic immunomodulators.
Calne Roy (22 Arrow Road Cambridge GB2 CB22AS), Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Gerhard Zenke DE; Hendrik Schuurman CH; Barbara Haeberlin CH; Armin Meinzer DE, Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin.
Smith ; III Amos B. (Merion PA) Condon Stephen M. (Philadelphia PA) Leazer ; Jr. Johnnie L. (Philadelphia PA) Maleczka Robert E. (Media PA) McCauley John A. (Philadelphia PA) Leahy James W. (San Lean, Processes and intermediates for preparing macrocycles.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Waranis Robert P. (Chazy NY) Harrison Maureen M. (St. Albans VT) Leonard Thomas W. (Plattsburgh NY) Enever Robin P. (Rouses Point NY), Rapamycin formulation for IV injection.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Weiner Alan L. (Cranbury NJ) Sinnett Kevin (Mukwonago WI) Johnson Sterling (Skillman NJ), Tack for intraocular drug delivery and method for inserting and removing same.
Haffner, David S.; Burns, Thomas W.; Heitzmann, Harold A.; Curry, Kenneth M., Implants with controlled drug delivery features and methods of using same.
Haffner, David S.; Burns, Thomas W.; Heitzmann, Harold A.; Curry, Kenneth M., Implants with controlled drug delivery features and methods of using same.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Astafieva, Irina; Horvath, Judit; Farinas, Kathleen Cogan; Bueche, Blaine; Erickson, Signe, Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.